C:\STNEXP4\QUERIES\10009477 (rce).str





chain nodes :
7 8 12 13 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7 4-12 4-13 5-15 5-16 6-17 6-18 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-12 4-13 5-15 5-16 6-17 6-18 7-8
exact bonds :
1-2 1-6 1-7 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,Cl,Br,F,I,Hy,[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 12:CLASS 13:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 20:CLASS
Generic attributes :
8:
Saturation : Unsaturated
19:
Saturation : Unsaturated
20:
Saturation : Saturated

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L1    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L2    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10009477 (rce).str

L3      STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1               SCR 1839
L2               SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3               STR
```

Ak 2

Cb 1



G1 H,Cl,Br,F,I,Hy,[@1],[@2]

```
Structure attributes must be viewed using STN Express query preparation.
L4              QUE  L3 AND L1 NOT L2


=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L5    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L6    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10009477 (rce).str

L7      STRUCTURE UPLOADED

=> que L7 AND L5 NOT L6

L8   QUE L7 AND L5 NOT L6

=> d 18
L8 HAS NO ANSWERS
L5              SCR 1839
L6              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L7              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L8              QUE  L7 AND L5 NOT L6


=> s l8 sss sam
SAMPLE SEARCH INITIATED 08:28:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   8720 TO ITERATE

 11.5% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       168806 TO   179994
PROJECTED ANSWERS:               1 TO      351

L9            1 SEA SSS SAM L7 AND L5 NOT L6

=> s l8 sss ful
FULL SEARCH INITIATED 08:29:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 174632 TO ITERATE

100.0% PROCESSED  174632 ITERATIONS                              71 ANSWERS
```

SEARCH TIME: 00.00.05

L10 71 SEA SSS FUL L7 AND L5 NOT L6

=> s l10
L11 34 L10

=> d l11 1-34 bib,ab,hitstr

L11 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:591156 CAPLUS
DN 139:149640
TI Preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain
IN Bakthavatchatam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.; Caldwell, Timothy M.; De Lombaert, Stephane
PA Neurogen Corporation, USA
SO PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062209	A2	20030731	WO 2003-US1563	20030117
	WO 2003062209	A3	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-349920P P 20020117
US 2002-350527P P 20020122
OS MARPAT 139:149640
AB Substituted quinazolin-4-ylamine analogs (shown as I; variables defined below; e.g. (4-trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine) are provided. Such compds. are ligands that may be used to modulate VR1 capsaicin receptor activity in vivo or in vitro (no data), and are particularly useful in the treatment of conditions assocd. with pathol. receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. For I; V, X, W, Y and Z are each independently N or CR1, with the proviso that at least one of V and X is N; U is N or CR2, with the proviso that if V and X are N, then U is CR2; R1 = H, halogen, hydroxy, amino, C1-C8 alkyl, haloC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkoxy and mono- and di(C1-C8alkyl)amino. R2 = (i) H, halogen, cyano, or -COOH; (ii) C1-C8alkanoyl, C2-C8alkanone, or C1-C8carbamate, each of which is (un)substituted with 1-9 substituents = Rb, or (iii) -Rc-M-A-Ry, wherein: Rc is C0-C3alkyl; M is a bond, N(Rz), O, S, SO2, (C:O)pN(Rz), N(Rz)(C:O)p, SO2N(Rz), or N(Rz)SO2, wherein p is 0 or 1; A is a bond or C1-C8alkyl, (un)substituted with 1-3 Rb. Ry and Rz, if present, are: (a) independently H, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C6-C10arylC1-C8alkyl, C2-C8alkyl ether, C1-C8alkoxy, a 4- to 10-membered carbocycle or heterocycle, or joined to R1 to form a 4- to 10-membered carbocycle or heterocycle, wherein each Ry and Rz = (un)substituted with 1-9 Rb; or (b) joined to form a 4- to 10-membered carbocycle or heterocycle that is (un)substituted with 1-9 Rb; Ar2 is a 5- to 7-membered arom. heterocycle, (un)substituted with 1-3 LRa. Ar1 is a 5- to 10-membered arom. carbocycle or heterocycle, (un)substituted with 1-3 LRa; L = bond, -O-, -C(O)-, -OC(O)-, -C(O)O-, -O-C(O)O-, -S(O)m-, -NRx-,

-C(O)NHRx-, -NHRxC(O)-, -NRxS(O)m-, -S(O)mNRx- and -N[S(O)mRx]S(O)m-; wherein m = 0, 1 and 2; and Rx = H and C1-C8alkyl; Ra = (i) H, halogen, cyano and nitro; and (ii) C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C2-C8alkyl ether, 3- to 10-membered heterocycles, mono- and di(C1-C8alkyl)amino and (3- to 10-membered heterocycle)C1-C6 alkyl, each of which is (un)substituted with 1-9 Rb. Rb = hydroxy, halogen, amino, aminocarbonyl, amido, cyano, nitro, C1-C8alkyl, C1-C8alkoxy, C1-C8alkylthio, C1-C8alkyl ether, hydroxyC1-C8alkyl, haloC1-C8alkyl, Ph, phenyl(C1-C8alkyl), mono and di(C1-C6 alkyl)amino, (SO2)C1-C8alkyl, 5- to 7-membered heterocycle and (5- to 7-membered heterocycle)(C1-C8alkyl). Although the methods of prepn. are not claimed, many example prepns. and characterization data for >500 examples of I are included.

IT **573683-86-0P**, [2-[(5,6-Dihydro-4H-pyrimidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detector; prepn. of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain and for detecting receptors)

RN 573683-86-0 CAPLUS

CN 4-Quinazolinamine, 2-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:221691 CAPLUS
DN 138:255245
TI Preparation of imidazo[1,2-a]pyrimidines and intermediates and fungicide compositions containing the same
IN Ikegami, Hiroshi
PA Sumitomo Chemical Company, Limited, Japan
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022850	A1	20030320	WO 2002-JP8718	20020829
	W: US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	JP 2003155287	A2	20030527	JP 2002-253211	20020830
PRAI	JP 2001-266881	A	20010904		

OS MARPAT 138:255245
AB Imidazo[1,2-a]pyrimidines represented by the general formula (I) have excellent control activity against plant diseases: wherein R1 and R2 are each C1-C6 alkyl which may be substituted with one or more members selected from the group consisting of C1-C4 alkoxy, C2-C8 dialkylamino, C1-C4 alkylthio, C2-C5 alkoxycarbonyl, cyano and halogen, or the like, or R1 and R2 together with the nitrogen atom to which they are bonded may form a group derived from a 3- to 8-membered heterocycle; R3 is halogeno or C1-C4 alkyl; and Ar is Ph which may be substituted with a halogen atom or the like. Thus, reaction of di-Et malonate and 1-bromo-2,4,6-trifluorobenzene in presence of catalyst formed di-Et (2,4,6-trifluorophenyl)malonate (II). Reaction of II with 2-aminoimidazole hydrochloric acid salt formed 5,7-dihydroxy-6-(2,4,6-trifluorophenyl)imidazo-[1,2-a]pyrimidine, which underwent chlorine substitution reaction to give 5,7-dichloro-6-(2,4,6-trifluorophenyl)imidazo-[1,2-a]pyrimidine (III). Reaction of III with 4-methylpiperidine gave 5-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-7-chloroimidazo-[1,2-a]pyrimidine (IV). III was tested to be an effective plant leaf fungicide.
IT **502500-62-1P 502501-73-7P 502502-33-2P**
502503-75-5P 502504-33-8P 502504-94-1P
RL: AGR (Agricultural use); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazo[1,2-a]pyrimidine derivs. and intermediates for fungicide compns.)
RN 502500-62-1 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 7-chloro-5-(5,6-dihydro-1(4H)-pyrimidinyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 502501-73-7 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 7-chloro-6-(2-chloro-6-fluorophenyl)-5-(5,6-dihydro-1(4H)-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 502502-33-2 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 7-chloro-6-(2,6-difluorophenyl)-5-(5,6-dihydro-1(4H)-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 502503-75-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 5-(5,6-dihydro-1(4H)-pyrimidinyl)-7-methyl-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 502504-33-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 6-(2-chloro-6-fluorophenyl)-5-(5,6-dihydro-1(4H)-pyrimidinyl)-7-methyl- (9CI) (CA INDEX NAME)



RN 502504-94-1 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 6-(2,6-difluorophenyl)-5-(5,6-dihydro-1(4H)-pyrimidinyl)-7-methyl- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:777929 CAPLUS
DN 137:294954
TI Preparation of 2-(4-substituted-2-oxo-1,2-dihydropyridin-3-yl)-benzimidazoles as novel tyrosine kinase inhibitors
IN Wittman, Mark D.; Balasubramanian, Neelakantan; Velaparthi, Upender; Zimmermann, Kurt; Saulnier, Mark G.; Liu, Peiying; Sang, Xiaopeng; Frennesson, David B.; Stoffan, Karen M.; Tarrant, James G.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002079192	A1	20021010	WO 2002-US9402	20020326

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-279327P P 20010328
OS MARPAT 137:294954
AB The title compds. [I; X = N, C, a bond, etc.; Y = O, S; W = N, C, O, S (if W = O or S, then R9 is absent); R1-R9 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts which inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents, were prepd. Thus, reacting 3-[6-(imidazol-1-yl)-4-methyl-1H-benzimidazol-2-yl]-4-iodo-1H-pyridin-2-one (prepn. given) with (S)-(-)-2-phenylglycinol in the presence of N-methylmorpholine in DMF afforded 52% (S)-II which showed IC50 of 1.0 .mu.M in cytotoxicity assay (HT-29 human colon tumor cell line). 30 Of the exemplified compds. I showed kinase activity of <25.mu.M against one or more of the following kinases CDK, EMT, FAK, Her1, Her2, IGF, IR, LCK, MET, PDGF, VEGF. The compds. I are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
IT **468740-83-2P 468740-84-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(4-substituted-2-oxo-1,2-dihydropyridin-3-yl)-benzimidazoles as novel tyrosine kinase inhibitors)
RN 468740-83-2 CAPLUS
CN 2(1H)-Pyridinone, 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-(5,6-dihydro-1(4H)-pyrimidinyl)-4-methyl-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468740-84-3 CAPLUS
CN 2(1H)-Pyridinone, 4-[[(2S)-2-(3-chloro-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-(5,6-dihydro-1(4H)-pyrimidinyl)-4-methyl-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:728879 CAPLUS
DN 137:263038
TI Preparation of triazoles as pharmaceuticals for treatment of autoimmune disease and inflammation
IN Tsuboi, Katsunori; Nakatsuka, Masashi; Kanai, Toshio; Fukuda, Nobuhisa
PA Sumitomo Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 80 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002275165	A2	20020925	JP 2001-300485	20010928
PRAI JP 2001-4881	A	20010112		

OS MARPAT 137:263038
AB The compds. I [M = single bond, O, S, SO, SO2, CQ, etc.; CQ = 1,3-dioxane ring, 1,3-dioxolane ring; Y1Y2 = H, halo, alkyl, haloalkyl, NO2, cyano, etc.; 0-3 Y1 and Y2 exists resp.; R8, R9 = H, alkyl; R8R9 = hydrocarbon ring; R7 = H, R28, COR28, SO2R28, CO2R28, etc.; R7 is connected with N in triazole ring; R28 = alkyl, alkenyl, alkynyl, aryl, etc.; L = N:C(NR2R3)NR1R4, NR1C(:NR4)NR2R3, NR5R6; R1-R4 = H, OH, NO2, cyano, R29, OR29, COR29, etc.; R29 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl; R5, R6 = H, OH, R29, OR29, COR29, etc.] or their pharmaceutically acceptable salts are prepd. 4,3-PhFC6H3CHMeCO2Et (20 g) was treated with aminoguanidine hydrochloride in the presence of NaOMe in EtOH under reflux for 13 h to give 4.0 g 3-[1-(2-fluoro-1,1'-biphenyl-4-yl)ethyl]-1H-1,2,4-triazole-5-amine showing good inhibitory activity against adjuvant arthritis in rats.
IT **321879-37-2P 462646-02-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of triazoles as pharmaceuticals for treatment of autoimmune disease and inflammation)
RN 321879-37-2 CAPLUS
CN Methanone, [3-[1-[5-[5,6-dihydro-2-(4-morpholinyl)-1(4H)-pyrimidinyl]-1H-1,2,4-triazol-3-yl]ethyl]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 462646-02-2 CAPLUS
CN Morpholine, 4-[1-[5-(1-[1,1'-biphenyl]-4-ylethyl)-1H-1,2,4-triazol-3-yl]-1,4,5,6-tetrahydro-2-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 462646-01-1
CMF C24 H28 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L11 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:615577 CAPLUS
DN 137:169536
TI Preparation of aryl-substituted tetrahydropyrimidines and related compounds as melanocortin-4 receptor binding compounds
IN Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062766	A2	20020815	WO 2002-US3566	20020207
	WO 2002062766	A3	20021003		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1363890	A2	20031126	EP 2002-718920	20020207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-778468	A	20010207		
	WO 2002-US3566	W	20020207		

OS MARPAT 137:169536
AB Title compds. I [wherein A and B = independently (un)substituted biaryl, (hetero)aryl, Ph, (cyclo)alkyl, (cyclo)alkoxy, alkenyl, alkynyl, OH, acyl(oxy), carbamoyl, amino, thiol, amidino, imino, NO2, N3, etc.; L1 and L2 =- covalent bond or (un)substituted alkyl optionally interrupted by O, S, or N; r = covalent bond, CH, CH2, CHR1, CR1R2, or H; t = CH, CH2, CHR3, CR3R4, or H; s = CHR5, CR5R6, or absent; R = H, (un)substituted alkyl, arylalkyl, or heteroalkyl, and may optionally be linked to A, B, L1, or L2; R1-R6 = independently (un)substituted alkyl, halo, thiol, thioether, thioalkyl, alkoxy, and may be optionally linked to each other to form addnl. ring moieties, e.g., quinoxalinyl; or pharmaceutically acceptable salts thereof] were prepd. as melanocortin-4 receptor binding (MC4-R) compds. For example, stirring a soln. of .alpha.-tolunitrile with diisopropylamine and BuLi in hexanes at -78.degree. under nitrogen for 1 h, followed by addn. of HMPA and 1-chloromethylnaphthalene in THF, afforded 2-(2-naphthalen-1-ylethyl)benzonitrile. Heating the benzonitrile with 1,3-diaminopropane in the presence of H2S at 80.degree. for 72 h gave the tetrahydropyrimidinyl cycloaddn. product II. The latter exhibited exemplary inhibition of MC4-R in a scintillation proximity assay. I are useful for the treatment of disorders assocd. with pigmentation, bones, or wt. loss (no data).
IT **326481-13-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MC4-R binding compd.; prepn. of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for

treatment of pigmentation, bone, and wt. loss disorders)

RN 326481-13-4 CAPLUS

CN Pyrimidine, 1,4,5,6-tetrahydro-1-(3-pyridinylmethyl)-2-[2-[(3-pyridinylmethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





L11 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:793434 CAPLUS
DN 135:339275
TI Cyclic amidines, nicotinic acetylcholine .alpha.4.beta.2 receptor activators containing them, and pharmaceuticals
IN Imoto, Masahiro; Iwanami, Tatsuya; Akabane, Minako; Tani, Yoshihiro
PA Suntory, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

Appl. PCT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001302643	A2	20011031	JP 2000-120976	20000421
	WO 2001081334	A2	20011101	WO 2001-JP3378	20010420
	WO 2001081334	A3	20020808		
	W: AU, CA, CN, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001048799	A5	20011107	AU 2001-48799	20010420
	EP 1280793	A2	20030205	EP 2001-921932	20010420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2003100769	A1	20030529	US 2001-9477	20011211
PRAI	JP 2000-120976	A	20000421		
	WO 2001-JP3378	W	20010420		

OS MARPAT 135:339275
AB The activators, useful for treatment of brain function disorders, contain cyclic amidines I [A1, A2 = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl; X = (un)substituted C2H4, (un)substituted CH:CH, (un)substituted (CH2)3, (un)substituted CH2CH2NH] or their salts. Trimethylenediamine was cyclocondensed with Et (6-chloro-3-pyridyl)acetate and treated with fumaric acid to give I fumarate (A1 = H, A2 = 6-chloro-3-pyridylmethyl, X = CH:CH), which showed affinity with rat nicotinic acetylcholine .alpha.4.beta.2 receptor with Ki of 29 nM, vs. 1.6 nM, for nicotine. Pharmaceutical formulations contg. I are given.
IT **371122-25-7P 371122-39-3P 371122-75-7P**
371122-81-5P 371122-83-7P 371122-85-9P
371122-87-1P 371122-92-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclic amidines as nicotinic acetylcholine .alpha.4.beta.2 receptor activators)
RN 371122-25-7 CAPLUS
CN Pyrimidine, 1-[(6-chloro-3-pyridinyl)methyl]-1,4,5,6-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-24-6
CMF C10 H12 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-39-3 CAPLUS
CN Pyrimidine, 1,2-bis[(6-chloro-3-pyridinyl)methyl]-1,4,5,6-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-38-2
CMF C16 H16 Cl2 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-75-7 CAPLUS
CN Pyrimidine, 1-[(5,6-dichloro-3-pyridinyl)methyl]-1,4,5,6-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-74-6
CMF C10 H11 Cl2 N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-81-5 CAPLUS
CN Pyrimidine, 1-[2-(6-chloro-3-pyridinyl)ethyl]-1,4,5,6-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-80-4
CMF C11 H14 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-83-7 CAPLUS
CN Pyridazine, 3-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-82-6

CMF C9 H12 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-85-9 CAPLUS
CN Pyrimidine, 1,4,5,6-tetrahydro-1-[(6-methyl-3-pyridinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-84-8
CMF C11 H15 N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-87-1 CAPLUS
CN Pyrimidine, 1,4,5,6-tetrahydro-1-(3-pyridinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-86-0

CMF C10 H13 N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 371122-92-8 CAPLUS
CN Pyrimidine, 1-[(2-chloro-5-thiazolyl)methyl]-1,4,5,6-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 371122-91-7
CMF C8 H10 Cl N3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **371122-24-6 371122-38-2 371122-74-6**
371122-80-4 371122-82-6 371122-84-8
371122-86-0 371122-91-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of cyclic amidines as nicotinic acetylcholine .alpha.4.beta.2 receptor activators)
RN 371122-24-6 CAPLUS
CN Pyrimidine, 1-[(6-chloro-3-pyridinyl)methyl]-1,4,5,6-tetrahydro- (9CI)

(CA INDEX NAME)



RN 371122-38-2 CAPLUS
CN Pyrimidine, 1,2-bis[(6-chloro-3-pyridinyl)methyl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 371122-74-6 CAPLUS
CN Pyrimidine, 1-[(5,6-dichloro-3-pyridinyl)methyl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 371122-80-4 CAPLUS
CN Pyrimidine, 1-[2-(6-chloro-3-pyridinyl)ethyl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 371122-82-6 CAPLUS
CN Pyridazine, 3-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 371122-84-8 CAPLUS
CN Pyrimidine, 1,4,5,6-tetrahydro-1-[(6-methyl-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 371122-86-0 CAPLUS
CN Pyrimidine, 1,4,5,6-tetrahydro-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 371122-91-7 CAPLUS
CN Pyrimidine, 1-[(2-chloro-5-thiazolyl)methyl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



L11 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:185754 CAPLUS
DN 134:237479
TI Preparation of 5-amino-substituted triazolopyridines for treating diseases related to the adenosine A2A receptor
IN Huber Trottmann, Gerda; Hunkeler, Walter; Jakob-Roetne, Roland; Kilpatrick, Gavin John; Nettekoven, Matthias Heinrich; Riemer, Claus
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 698 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017999	A2	20010315	WO 2000-EP8372	20000828
	WO 2001017999	A3	20011206		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6355653	B1	20020312	US 2000-645127	20000824
	BR 2000013792	A	20020514	BR 2000-13792	20000828
	EP 1214322	A2	20020619	EP 2000-964043	20000828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003528811	T2	20030930	JP 2001-522222	20000828
	NO 2002001077	A	20020305	NO 2002-1077	20020305
PRAI	EP 1999-117578	A	19990906		
	WO 2000-EP8372	W	20000828		

OS MARPAT 134:237479
AB The title compds. [I; R1 = (un)substituted 5-6 membered heteroaryl, contg. 1-3 heteroatoms selected from N, O, S (wherein the heteroaryl may be optionally linked to the pyrazole ring via an alkylene or alkenylene), (un)substituted Ph, O(CH2)nPh, etc.; R2, R4 = H, CN, SO2Ph; R3 = H, halo, (un)substituted 5-6 membered heteroaryl, contg. 1-3 heteroatoms, selected from N, O or S, etc.; R5 = NR2 (wherein R = H, alkyl, Ph, etc.); n = 0-4], useful for the treatment of diseases related to the adenosine A2A receptor, were prepd. and formulated. Thus, treating 5-bromo-2-methoxypyridine with acrylonitrile in the presence of Et3N and Pd(PPh3)2Cl2 in DMF followed by reaction of the resulting 3-(6-methoxypyridin-3-yl)acrylonitrile with 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole (prepn. given) in the presence of NaH afforded I [R1 = 2-furyl; R2, R4 = H; R3 = 6-methoxypyridin-3-yl; R5 = NH2] which showed pKi of 7.9 in the human A2A binding assay.
IT **329972-24-9P 329973-39-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5-amino-substituted triazolopyridines for treating diseases related to the adenosine A2A receptor)
RN 329972-24-9 CAPLUS
CN Benzoic acid, 2-[1,4,5,6-tetrahydro-1-[2-phenyl-7-(4-

pyridinyl)[1,2,4]triazolo[1,5-a]pyridin-5-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 329973-39-9 CAPLUS
CN Benzoic acid, 2-[1-(2,7-di-2-pyridinyl[1,2,4]triazolo[1,5-a]pyridin-5-yl)-1,4,5,6-tetrahydro-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:63983 CAPLUS
DN 134:131527
TI Preparation and effect of heteroaromatic ring compounds against autoimmune disorders and chronic inflammation
IN Nakatsuka, Masashi; Nakatani, Shogo; Okada, Shin-ichiro; Tsuboi, Katsunori; Nishikaku, Fumio
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005774	A1	20010125	WO 2000-JP4616	20000710
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1201661	A1	20020502	EP 2000-944389	20000710
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	JP 1999-201447	A	19990715		
	JP 2000-58217	A	20000303		
	WO 2000-JP4616	W	20000710		

OS MARPAT 134:131527
AB Title compds. [I; R1 = F, C6H5CO, C6H5CHO2(CH2)2; R2 = H, C6H5; R3 = H, CH3; R4 = H, CH3; R5 = CH3, CH2CH2N[(CH2)2]O; R6 = H, CH3; R4-R5 = CH2CH2OCH2CH2, CH2CH2SCH2CH2, CH2CH2S(:O)(:O)CH2CH2; R6 = H, CH3; R7 = CH3, H, CH2CH2OH, CN, C(NH)N[(CH2)2]2O; R5-R7 = CH2CH2, CH2CH2CH2, CH2CHOHCH2; R6-R7 = CH2CH2OCH2CH2; R8 = H, CH3; R9 = H, CH3; X = N, NCH3, S; Y = NCH3, S, NH, NSO2C6H5; Z = CH, O, S, N; dotted line = single, double bond] and pharmaceutically acceptable salts exhibiting excellent phys. properties and potent ameliorative effects against both immune disorders and chronic inflammation are prepd. Thus, the title compd. II was prepd. and tested.
IT **321879-37-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and effect of heteroarom. ring compds. against immune disorders and chronic inflammation)
RN 321879-37-2 CAPLUS
CN Methanone, [3-[1-[5-[5,6-dihydro-2-(4-morpholinyl)-1(4H)-pyrimidinyl]-1H-1,2,4-triazol-3-yl]ethyl]phenyl]phenyl- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:769086 CAPLUS
DN 133:335159
TI Preparation of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants
IN Arnaiz, Damian O.; Chou, Yuo-ling; Griedel, Brian D.; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Steven T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun
PA Berlex Laboratories, Inc., USA
SO U.S., 113 pp., Cont.-in-part of U.S. Ser. No. 994,284, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6140351	A	20001031	US 1998-187459	19981105
	CA 2315070	AA	19990701	CA 1998-2315070	19981127
	WO 9932477	A1	19990701	WO 1998-EP7650	19981127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9918759	A1	19990712	AU 1999-18759	19981127
	AU 751856	B2	20020829		
	EP 1040108	A1	20001004	EP 1998-963519	19981127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001526283	T2	20011218	JP 2000-525414	19981127
	NZ 503809	A	20020426	NZ 1998-503809	19981127
	ZA 9811599	A	19990817	ZA 1998-11599	19981217
	NO 2000003111	A	20000818	NO 2000-3111	20000616
	US 6380221	B1	20020430	US 2000-631450	20000803
	US 6498185	B1	20021224	US 2000-631452	20000803
PRAI	US 1997-994284	B2	19971219		
	US 1998-187459	A	19981105		
	WO 1998-EP7650	W	19981127		

OS MARPAT 133:335159
AB REZDR3 [I; D,E = Z1NR5C(:X), Z1NR5SO0-2, etc.; R,R3 = (un)substituted heterocyclyl or -aryl; R5 = H, (ar)alkyl, aryl; X = O, S, H2; Z = (un)substituted heterocyclylene or -arylene; Z1 = bond, alkylene, alkylidene, etc.] were prepd. as factor Xa, thrombin, and prothrombinase inhibitors. Thus, H2NZCONHC6H4Cl-4 (Z = 4-chloro-1,2-phenylene)(prepn. given) was N-acylated by 3-chloro-4-chloromethyl-2-thiophenecarbonyl chloride and the product aminated by 1-methylpiperazine to give title compd. II. Data for biol. activity of I were given.
IT **229336-18-9P 229340-52-7P 229343-43-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants)
RN 229336-18-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229340-52-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-18-9
CMF C23 H20 Cl3 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 229343-43-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5,6-dihydro-5-hydroxy-1(4H)-pyrimidinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229343-42-4
CMF C23 H20 Cl3 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688225 CAPLUS
DN 133:252445
TI Preparation of fused pyridopyridazine inhibitors of cGMP phosphodiesterase
IN Yu, Guixue; Macor, John; Chung, Hyei-jha; Humora, Michael; Katipally, Kishta; Wang, Yizhe; Kim, Soojin
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056719	A1	20000928	WO 2000-US6100	20000309
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1165521	A1	20020102	EP 2000-916180	20000309
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 765128	B2	20030911	AU 2000-37327	20000309
	US 6316438	B1	20011113	US 2000-526162	20000315
PRAI	US 1999-125488P	P	19990322		
	US 1999-148009P	P	19990810		
	WO 2000-US6100	W	20000309		

OS MARPAT 133:252445
AB The title compds. [I; Y = N, CR5; Z = N, CR6 (provided that at least one of Y and Z = N); R1, R2 = H, halo, SR7, etc.; R3 = H, alkyl, arylalkyl; R4 = H, halo, alkyl, etc.; R5, R6 = H, halo, alkyl; R7 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts, inhibitors of cGMP PDE, esp. type 5, useful in treating cardiovascular and sexual disorders, were prepd. E.g., a multi-step synthesis of I [Y = N; Z = CH; R1 = 4-hydroxypiperidin-1-yl; R2 = (3-Cl-4-MeOC6H3)CH2NH; R3 = Et; R4 = H] was given. Compds. I are effective at 0.05-100 mg/kg/day.
IT **296250-13-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of fused pyridopyridazine inhibitors of cGMP phosphodiesterase)
RN 296250-13-0 CAPLUS
CN Pyrimidine, 1-[[1-[9-[[(3-chloro-4-methoxyphenyl)methyl]amino]-3-ethyl-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-yl]-1H-imidazol-4-yl]carbonyl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:126254 CAPLUS
DN 128:204878
TI Preparation of pyrazinobenzothiazine derivatives and analogs for the treatment of inflammation and autoimmune diseases
IN Kaneko, Toshihiko; Clark, Richard; Ohi, Norihito; Ozaki, Fumihiro; Kawahara, Tetsuya; Kamada, Atsushi; Okano, Kazuo; Yokohama, Hiromitsu; Muramoto, Kenzo; Arai, Tohru; Ohkuro, Masayoshi; Takenaka, Osamu; Sonoda, Jiro
PA Eisai Co., Ltd., Japan; Kaneko, Toshihiko; Clark, Richard; Ohi, Norihito; Ozaki, Fumihiro; Kawahara, Tetsuya; Kamada, Atsushi; Okano, Kazuo; Yokohama, Hiromitsu; et al.
SO PCT Int. Appl., 1344 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806720	A1	19980219	WO 1997-JP2787	19970808
	W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9737849	A1	19980306	AU 1997-37849	19970808
	ZA 9707103	A	19990208	ZA 1997-7103	19970808
	EP 934941	A1	19990811	EP 1997-934750	19970808
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 6518423	B1	20030211	US 1999-230852	19990405
PRAI	JP 1996-210344	A	19960809		
	WO 1997-JP2787	W	19970808		

OS MARPAT 128:204878
AB The title compds. I [R1 to R3 are the same or different and each represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, etc., provided that when R1 to R3 are all optionally substituted lower alkyl groups, they do not simultaneously represent Me groups; R represents hydrogen, lower alkyl, etc.; E represents N, C, etc.; Z represents O, S, SO, SO2, etc.; and the ring G represents an optionally substituted heteroaryl ring having at least one nitrogen atom] are prepd. I are useful in the treatment and prevention of inflammatory immunol. diseases, autoimmune diseases, rheumatism, collagen disease, asthma, nephritis, ischemic reflow disorders, psoriasis, atopic dermatitis or rejection reactions following organ transplantation. The compd. (syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[3.3.1]nona-9-yl]acetic acid (II) at 10 mg/kg orally gave 65% inhibition of carrageenin-induced inflammation in rats. II in vitro showed IC50 of 2.3 .mu.M against the expression of ICAM-1.
IT **203659-68-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazinobenzothiazine derivs. and analogs for treatment of inflammation and autoimmune diseases)
RN 203659-68-1 CAPLUS
CN 1H-Pyrazino[2,3-b][1,4]benzothiazine, 8-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:577408 CAPLUS
DN 125:276744
TI Synthesis and radical polymerization of novel vinyl monomers having a imidazoline and pyrimidine moiety
AU Seckin, Turgay; Alici, Bulent; Cetinkaya, Engin; Ozdemir, Ismail
CS Fac. Art Sci. Chem., Inonu Univ., Malatya, TR-44069, Turk.
SO Polymer Bulletin (Berlin) (1996), 37(4), 443-450
CODEN: POBUDR; ISSN: 0170-0839
PB Springer
DT Journal
LA English
AB Alkylation of the methylene-bridged tetrahydropyrimidine derivs. by chloromethylstyrene produces bridged bis(4-vinylbenzyl)-1,4,5,6-tetrahydropyrimininum salts in high yields. Similar procedures are used to prep. 2-imidazolinium derivs. The quaternary salts which support functional side groups of potential biomedical interest are characterized by spectroscopic methods. These monomers are readily polymd. free radically in DMF soln. at moderate temps. The sol. and insol. polymers contg. 2-imidazolinium and 1,4,5,6-tetrahydropyrimidinum salts exhibited antibacterial activities against Escherichia coli.
IT **182947-47-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and polymn. of vinyl monomers having a imidazoline or pyrimidine moiety)
RN 182947-47-3 CAPLUS
CN Pyrimidine, 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



Same as #16

S

L11 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:219295 CAPLUS
DN 122:10060
TI Preparation of 1-(3-pyridyl)-2-(dihalonitromethyl)-1,3-diazacyclopent-2-enes and -diazacyclohex-2-enes as pesticides.
IN Munro, David; Patel, Bipin
PA Shell Internationale Research Maatschappij B.V., Neth.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9422851	A1	19941013	WO 1994-EP1089	19940406
	W: AU, BR, CA, CN, HU, JP, KR, KZ, RU, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9465393	A1	19941024	AU 1994-65393	19940406
	ZA 9402392	A	19950116	ZA 1994-2392	19940407
PRAI	EP 1993-302748		19930407		
	WO 1994-EP1089		19940406		

OS CASREACT 122:10060; MARPAT 122:10060
AB Title compds. [I; n = 1, 2; R1 = (substituted) 3-pyridyl group; R2 = H, alkyl, haloalkyl; X, X1 = halo], were prepd. Thus, 2-nitromethylene-1-(6-methoxy-3-pyridyl)hexahydropyrimidine was stirred with N-chlorosuccinimide in CCl4 for 24 h to give 1-(6-methoxy-3-pyridyl)-2-(dichloronitromethyl)-1,3-diazacyclohex-2-ene. I showed a toxicity index [[LC50 (parathion)/LC50 (I)] .times. 100] = 1000-28000 against Nephotettix cincticeps.
IT **159336-02-4P 159336-06-8P 159336-07-9P**
159336-09-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(dihalonitromethyl)-1,3-diazacyclopent-2-enes and -diazacyclohex-2-enes as pesticides)
RN 159336-02-4 CAPLUS
CN Pyrimidine, 2-(dichloronitromethyl)-1,4,5,6-tetrahydro-1-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 159336-06-8 CAPLUS
CN Pyrimidine, 1-(6-bromo-3-pyridinyl)-2-(dichloronitromethyl)-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 159336-07-9 CAPLUS
CN Pyrimidine, 1-(6-chloro-3-pyridinyl)-2-(dichloronitromethyl)-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 159336-09-1 CAPLUS
CN Pyrimidine, 1-(6-chloro-3-pyridinyl)-2-(difluoronitromethyl)-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



L11 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:106926 CAPLUS
DN 120:106926
TI Novel syntheses of tricyclic, N-aryl, pyridine- and pyrazine-fused pyrimidones
AU Friary, Richard; McPhail, Andrew T.; Seidl, Vera
CS Schering-Plough Res. Inst., Kenilworth, NJ, 07033-0539, USA
SO Collection of Czechoslovak Chemical Communications (1993), 58(5), 1133-50
CODEN: CCCCAK; ISSN: 0010-0765
DT Journal
LA English
OS CASREACT 120:106926
AB 2-Methylthio-2-imidazoline and 2-methylthio-1,4,5,6-tetrahydro-2-pyrimidine amidated 2-chloro-3-pyridine- and 2-chloro-3-pyrazinecarbonyl chlorides. The products, (pyridinyl/pyrazinylcarbonyl)imidazoles and -pyrimidines I (X = CH, N, n = 1, 2), reacted with ArNH2 (Ar = Ph, substituted Ph) forming a series of tricyclic, linearly fused N-aryl pyrimidones II. Included among these pyrimidones were 10-aryl-2,3-dihydroimidazo[1,2-a]pyrido[2,3-d]pyrimidin-5(10H)-ones, 11-aryl-2,3,4,11-tetrahydropyrido[2,3-d]pyrimido[1,2-a]pyrimidin-6(6H)-ones, 10-aryl-2,3-dihydroimidazo[1,2-a]pyrazino[2,3-d]pyrimidin-5(10H)-ones, and 11-aryl-2,3,4,11-tetrahydropyrimido[1,2-a]pyrazino[2,3-d]pyrimidin-6(6H)-ones. 4,5,6,7-Tetrahydro-2-(methylthio)1H-1,3-diazepine amidated the Et hydrogen carbonate of 2-(phenylamino)-3-pyridinecarboxylic acid, forming 12-phenyl-2,3,4,5-tetrahydropyrido[2',3':4,5]pyrimido[1,2-a][1,3]diazepine-7(12H)-one. A single-crystal X-ray anal. and an unambiguous synthesis established the structure of the linearly fused isomer 10-phenyl-2,3-dihydroimidazo[1,2-a]pyrido[2,3-d]pyrimidin-5(10H)-one.
IT **108409-42-3P 108409-44-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclocondensation of, with arylamines)
RN 108409-42-3 CAPLUS
CN Pyrimidine, 1-[(2-chloro-3-pyridinyl)carbonyl]-1,4,5,6-tetrahydro-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 108409-44-5 CAPLUS
CN Pyrimidine, 1-[(3-chloropyrazinyl)carbonyl]-1,4,5,6-tetrahydro-2-(methylthio)- (9CI) (CA INDEX NAME)



L11 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:448211 CAPLUS
DN 117:48211
TI Preparation of 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds as antimicrobial agents
IN Murata, Masayoshi; Chiba, Toshiyuki; Tsutsumi, Hideo; Yamada, Akira; Hattori, Kohji
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9202521	A1	19920220	WO 1991-JP997	19910725
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 04234886	A2	19920824	JP 1991-196181	19910308
JP 06503803	T2	19940428	JP 1991-512378	19910725
PRAI GB 1990-16507		19900727		
JP 1991-196181		19910308		
GB 1990-5265		19900308		
WO 1991-JP997		19910725		

OS MARPAT 117:48211
AB The title compds. [I; R1 = (protected) carboxy; R2 = (protected) hydroxyalkyl; R3 = azetidinyl, pyrrolidinyl, imidazolidinyl, etc.; R10 = H, alkyl; A = alkylene] are prepd. A soln. of 5.14 g triester II in THF and EtOH was treated with Ph3P, dimedone, HOAc, and (Ph3P)4Pd with stirring at room temp., the ppt. was worked up and treated with MeC(:NH)OEt.HCl at pH 8.5 to give 0.49 g III. One I showed MIC of .ltoreq.0.025 .mu.g/mL against Staphylococcus epidermidis 89.
IT **142255-21-8P 142255-23-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antimicrobial agent)
RN 142255-21-8 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[(5,6-dihydro-2-methyl-1(4H)-pyrimidinyl)methyl]-6-(1-hydroxyethyl)-7-oxo-, [5R-[5.alpha.,6.alpha.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142255-23-0 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-6-(1-hydroxyethyl)-7-oxo-, [5R-[5.alpha.,6.alpha.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:471646 CAPLUS
DN 115:71646
TI Preparation of bicyclic pyrimidine derivatives and pharmaceutical compositions containing them for treatment of hypoxemia
IN Sakuma, Yasuji; Hasegawa, Masaichi; Kataoka, Kenichiro; Hoshina, Kenji; Yamazaki, Noboru; Kadota, Takashi; Yamaguchi, Hisao
PA Teijin Ltd., Japan
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9105784	A1	19910502	WO 1990-JP1313	19901011
W: AU, CA, HU, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, NL, SE				
CA 2067221	AA	19910412	CA 1990-2067221	19901011
CA 2067221	C	19970415		
AU 9065220	A1	19910516	AU 1990-65220	19901011
AU 645504	B2	19940120		
EP 495982	A1	19920729	EP 1990-914955	19901011
EP 495982	B1	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
AT 139232	E	19960615	AT 1990-914955	19901011
ES 2087916	T3	19960801	ES 1990-914955	19901011
JP 2541702	B2	19961009	JP 1990-513974	19901011
US 5378700	A	19950103	US 1992-839769	19920609
PRAI JP 1989-264763		19891011		
WO 1990-JP1313		19901011		

OS MARPAT 115:71646
AB The title compds. [I; R1-R3 = (un)substituted alkyl, alkenyl, arylalkyl, arylalkenyl, or alkylcarbonyl; provided that R1 = R2 .noteq. H; or NR2R3 = cyclic amino; Y = Q, piperazine-1,4-diyl, homopiperazine-1,4-diyl, NH, alkylimino, O, S; n = 4-6; Z = H, CO2H, OH, (un)substituted alkyl, aryl, etc.; or YZ = (un)substituted alkyl, alkenyl, or arylalkyl, 5- to 7-membered monocyclic N heterocyclyl optionally contg. O or S, 5- to 7-membered bicyclic N heterocyclyl; m = 1-3], useful for the treatment of hypoxemia caused by diseases of the respiratory system, are prepd. Thus, 43 g tetrahydropyrido[2,3-d]pyrimidine (II; X = Cl), 22 g LiI, and 300 mL N-methylpiperazine was stirred 15 h at 160.degree. in an autoclave to give 69% II (X = N-methylpiperazin-1-yl) (III) which was treated with satd. HCl in Et2O to give 87% III.HCl. II (X = NHCH2CH2Ph) at 0.1 mg/kg/min for 10 min i.v. increased by 17.4 mmHg the partial pressure of O in the arterial blood of rats having hypoxemia caused by injection of 2.0% AcOH 0.6 mL/kg into the airway. A total of 74 I and 58 acid addn. salts were prepd. An injection and tablet formulation contg. III were described.
IT **134703-81-4P 135196-80-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as drug for treatment of hypoxemia)
RN 134703-81-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-2-amine, 4-(5,6-dihydro-1(4H)-pyrimidinyl)-5,6,7,8-tetrahydro-N,8-di-2-propenyl- (9CI) (CA INDEX NAME)



RN 135196-80-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-2-amine, 4-(5,6-dihydro-1(4H)-pyrimidinyl)-5,6,7,8-tetrahydro-N,8-di-2-propenyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 134703-81-4
CMF C17 H24 N6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L11 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:407208 CAPLUS
DN 107:7208
TI Pyrimidine derivatives having antiallergy, antiinflammatory, and immunosuppressant activity
IN Friary, Richard James; Siegel, Marvin Ira; Smith, Sidney Randal
PA Schering Corp., USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8606375	A2	19861106	WO 1986-US899	19860501
	WO 8606375	A3	19870226		
	W: AU, DK, FI, HU, JP, KR				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8658656	A1	19861118	AU 1986-58656	19860501
	EP 220282	A1	19870506	EP 1986-903052	19860501
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4725596	A	19880216	US 1986-897169	19860815
PRAI	US 1985-729334		19850501		
	WO 1986-US899		19860501		

AB The title compds. [I; R = H, C1-6 alkyl, CH2CH2OH, CHO, acyl, (substituted) Bz or sulfonyl, carboxyalkyl, aminoalkyl; R1 = (substituted) Ph, pyridyl, furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl; X = CH, CH2, N, NR; Y = O, S; Z = (CR2R3)m, (CR2:CR3)p; R2, R3 = H, alkyl; R2R3 = bond; m = 2-6; n = 0, 1; P = 1-3] were prepd. as allergy and inflammation inhibitors and as immunosuppressants. Thus, 2-chloronicotinoyl chloride was amidated with 2-(methylthio)-2-imidazoline-HI and the product cyclocondensed with PhNH2 to give pyridoimidazopyrimidinone II. In guinea pigs 2 mg II/kg orally inhibited anaphylactic bronchospasms.

IT **108409-42-3P 108409-44-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclocondensation of, with phenylamine deriv.)

RN 108409-42-3 CAPLUS
CN Pyrimidine, 1-[(2-chloro-3-pyridinyl)carbonyl]-1,4,5,6-tetrahydro-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 108409-44-5 CAPLUS
CN Pyrimidine, 1-[(3-chloropyrazinyl)carbonyl]-1,4,5,6-tetrahydro-2-(methylthio)- (9CI) (CA INDEX NAME)


N
O
N
C
N
Cl
MeS
N

L11 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:28848 CAPLUS
DN 106:28848
TI Heterocyclic compounds
IN Shiokawa, Kozo; Tsuboi, Shinichi; Kagabu, Shinzo; Moriya, Koichi
PA Nihon Tokushu Noyaku Seizo K. K., Japan
SO Eur. Pat. Appl., 271 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 192060	A1	19860827	EP 1986-100708	19860117
	EP 192060	B1	19910918		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL				
	JP 61178981	A2	19860811	JP 1985-18627	19850204
	JP 06006585	B4	19940126		
	JP 61178982	A2	19860811	JP 1985-18628	19850204
	JP 06049699	B4	19940629		
	JP 61183271	A2	19860815	JP 1985-23683	19850212
	JP 07000613	B4	19950111		
	JP 61267561	A2	19861127	JP 1985-106853	19850521
	JP 06029258	B4	19940420		
	JP 61267575	A2	19861127	JP 1985-106854	19850521
	JP 05014716	B4	19930225		
	JP 62081382	A2	19870414	JP 1985-219082	19851003
	JP 07030070	B4	19950405		
	AT 67493	E	19911015	AT 1986-100708	19860117
	US 4742060	A	19880503	US 1986-821621	19860121
	AU 8652866	A1	19860807	AU 1986-52866	19860130
	AU 584388	B2	19890525		
	IL 77750	A1	19891031	IL 1986-77750	19860131
	CA 1276018	A1	19901106	CA 1986-500793	19860131
	DK 8600519	A	19860805	DK 1986-519	19860203
	ZA 8600763	A	19860924	ZA 1986-763	19860203
	BR 8600428	A	19861021	BR 1986-428	19860203
	DD 242742	A5	19870211	DD 1986-286723	19860203
	HU 41954	A2	19870629	HU 1986-466	19860203
	HU 200651	B	19900828		
	CS 255867	B2	19880315	CS 1986-754	19860203
	PL 149199	B1	19900131	PL 1986-257774	19860203
	HU 202365	B	19910328	HU 1989-5815	19860203
	ES 551629	A1	19871201	ES 1986-551629	19860204
	US 4845106	A	19890704	US 1987-68991	19870701
	ES 557616	A1	19880216	ES 1987-557616	19870709
	ES 557617	A1	19880216	ES 1987-557617	19870709
	ES 557618	A1	19880216	ES 1987-557618	19870709
	US 5001138	A	19910319	US 1989-347836	19890504
	US 5204360	A	19930420	US 1990-557292	19900724
	US 5298507	A	19940329	US 1992-832174	19920206
	JP 05194490	A2	19930803	JP 1992-235152	19920812
	JP 07020953	B4	19950308		
	DK 9201042	A	19920821	DK 1992-1042	19920821
	DK 172809	B1	19990726		
	US 5461167	A	19951024	US 1993-67642	19930525
	US 5428032	A	19950627	US 1993-169902	19931220
	US 5580889	A	19961203	US 1995-404849	19950315

	US 5750704	A	19980512	US 1996-662096	19960612
	US 6022967	A	20000208	US 1998-12620	19980123
	US 6297374	B1	20011002	US 1999-309988	19990511
PRAI	JP 1985-18627	A	19850204		
	JP 1985-18628	A	19850204		
	JP 1985-23683	A	19850212		
	JP 1985-106853	A	19850521		
	JP 1985-106854	A	19850521		
	JP 1985-219082	A	19851003		
	EP 1986-100708	A	19860117		
	US 1986-821621	A3	19860121		
	US 1987-68991	A3	19870701		
	US 1989-347836	A3	19890504		
	US 1990-557292	A3	19900724		
	US 1992-832174	A3	19920206		
	US 1993-67642	A3	19930525		
	US 1993-169902	A3	19931220		
	US 1995-404849	A3	19950315		
	US 1996-662096	A3	19960612		
	US 1998-12620	A3	19980123		

OS CASREACT 106:28848

AB I (R, R1, R2, R5, R6 = H, alkyl; R3,R4 = H, OH, alkyl; n = 0, 1; X = O, S, NR7, CHR8; Y = N, CR9; Z = 5- or 6-membered heterocyclic group; R7 = H, halo, OH, alkoxy, benzyloxy, alkyl, etc.; R8 = H, alkyl, aryl, benzyl; R9 = H, halo, OH, alkoxy etc.) were prepd. as insecticides. Thus, a mixt. of 4.3 g N-(2-chloro-5-pyridylmethyl)-3-aminopropanethiol and 4.3 g 1-nitro-2,2-bis(methylthio)ethylene in EtOH was refluxed for 10 h to give 1.3 g 3-(2-chloro-5-pyridylmethyl)-2-nitromethylenetetrahydro-2H-1,3-thiazine (II). II, 200 ppm, totally controlled peach leaf louse (Myzodes persicae) on egg plant in the lab.

IT **105828-00-0P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)

RN 105828-00-0 CAPLUS

CN 2-Propenoic acid, 3-nitro-3-[1,4,5,6-tetrahydro-1-(4-pyridinylmethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:70362 CAPLUS
DN 104:70362
TI Poly(vinyl chloride) plastisols containing adhesion-promoting additives and their use as coatings
IN Hurnik, Helmut; Groegler, Gerhard; Hess, Heinrich; Kopp, Richard
PA Bayer A.-G. , Fed. Rep. Ger.
SO Ger. Offen., 52 pp.
CODEN: GWXXBX
DT Patent
LA German

Same as #19

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3403497	A1	19850808	DE 1984-3403497	19840202
	EP 150803	A2	19850807	EP 1985-100640	19850123
	EP 150803	A3	19860212		
	EP 150803	B1	19880615		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 35144	E	19880715	AT 1985-100640	19850123
	US 4623686	A	19861118	US 1985-694562	19850124
	CA 1255042	A1	19890530	CA 1985-472920	19850125
	DK 8500481	A	19850803	DK 1985-481	19850201
	ZA 8500792	A	19850925	ZA 1985-792	19850201
	ES 540068	A1	19851116	ES 1985-540068	19850201
	JP 60188475	A2	19850925	JP 1985-17757	19850202
PRAI	DE 1984-3403497		19840202		
	EP 1985-100640		19850123		

AB The title compns. have good storage stability and contain PVC plastisols and finely divided polyisocyanates with retarded activity (i.e., prepd. by reaction of NCO groups with reactive compds.) as well as plasticizers and/or slightly branched, plastisol-compatible polyols m. <60.degree.. Thus, a suspension of 56 g monomer-free trimerized 2,4-TDI (polyisocyanurate with 15.5% NCO, particle size .apprx.10 .mu.) in 100 g DOP was mixed with 0.4 g 4,4'-methylenebis(2-methylcyclohexanamine) (I) to prep. a compn. which was stable even after the addn. of 17 g 2,4(or 6)-diamino-3,5-diethyltoluene at 40-60.degree. (without I, the suspension solidified in a few minutes). Adding 5.6 g of the I-contg. suspension to 100 g plastisol (1 kg PVC in 700 g DOP) gave a coating compn. which had a const. viscosity during >30 days (without I, the plastisol thickened after 1 day) and was applied to nylon 66 fabric to give a coating with adhesion 185 N/5 cm.

IT **83613-32-5D**, reaction products with polyisocyanates
RL: USES (Uses)
(adhesion promoter, PVC plastisol contg., stable)
RN 83613-32-5 CAPLUS
CN Pyrimidine, 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:598718 CAPLUS
DN 97:198718
TI Tetrahydropyrimidines and their use as catalysts in production of polyurethane plastics
IN Rasshofer, Werner; Groegler, Gerhard; Kopp, Richard
PA Bayer A.-G. , Fed. Rep. Ger.
SO Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DT Patent
LA German

Same as #19

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 54876	A1	19820630	EP 1981-110409	19811214
	R: BE, DE, FR, GB, IT, NL				
	DE 3049131	A1	19820715	DE 1980-3049131	19801224
	JP 57130976	A2	19820813	JP 1981-206318	19811222
	US 4665177	A	19870512	US 1985-762347	19850805
PRAI	DE 1980-3049131		19801224		
	EP 1981-110409		19811214		
	US 1981-332064		19811218		
	JP 1981-206318		19811222		

AB 1,2-bis(tetrahydro-2-methylpyrimidin-1-yl)ethane [**83613-32-5**], 1,7-bis(tetrahydro-2-methylpyrimidin-1-yl)-4-methyl-4-azaheptane (I) [83613-34-7], 1-[3-(dimethylamino)propyl]tetrahydro-2-methylpyrimidine [83613-35-8] and several similar pyrimidine derivs. (as well as salts or complexes) are prepd. and used as catalysts for the prepn. of polyurethanes. The catalysts are resistant to hydrolysis and have little or no odor. Thus, [H2N(CH2)3NH(CH2)3]2NMe [83613-41-6] and MeCOCH2CO2Et [141-97-9] were used to prep. I. A mixt. of alkoxylated trimethylolpropane 80, HOCH2CH2OH 7, dibutyltin dilaurate 0.5, Cl3CF 12, I 0.4, and an isophorone diisocyanate-propoxylated glycerol prepolymer 41 g was used to prep. a polyurethane integral foam. The start time and cure time were 21 s and 122 s, resp.

IT **83613-32-5P 83613-36-9P 83613-37-0P**
83613-39-2P 83613-40-5P
RL: PREP (Preparation)
(prepn. of and catalysis of polyurethane formation by)

RN 83613-32-5 CAPLUS
CN Pyrimidine, 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 83613-36-9 CAPLUS
CN Carbonic acid, compd. with 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro-2-methylpyrimidine] (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 83613-32-5
CMF C12 H22 N4



CM 2

CRN 463-79-6
CMF C H2 O3



RN 83613-37-0 CAPLUS
CN Phenol, compd. with 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro-2-methylpyrimidine] (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 83613-32-5
CMF C12 H22 N4



CM 2

CRN 108-95-2
CMF C6 H6 O



RN 83613-39-2 CAPLUS
CN Hexanoic acid, 2-ethyl-, compd. with 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro-2-methylpyrimidine] (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 83613-32-5
CMF C12 H22 N4



CM 2

CRN 149-57-5
CMF C8 H16 O2



RN 83613-40-5 CAPLUS
CN Pyrimidine, 1,1'-(1,2-ethanediyl)bis[1,4,5,6-tetrahydro-2-methyl-, diacetate (9CI) (CA INDEX NAME)

CM 1

CRN 83613-32-5
CMF C12 H22 N4



CM 2

CRN 64-19-7
CMF C2 H4 O2



L11 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:142520 CAPLUS
DN 96:142520
TI Studies on .beta.-lactams. Part 59. A convenient synthesis of .alpha.-amido-.beta.-lactams
AU Bose, Ajay K.; Manhas, M. S.; Van der Veen, J. M.; Amin, S. G.; Fernandez, I. F.; Gala, K.; Gruska, R.; Kapur, J. C.; Khajavi, M. S.; et al.
CS Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, 07030, USA
SO Tetrahedron (1981), 37(13), 2321-34
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
AB A method is described for the prepn. of a no. of .alpha.-amido-.beta.-lactams starting from an azomethine and H2NCH2CO2H, protected as a Dane salt by reaction with a .beta.-dicarbonyl compd. Stereospecific condensation reaction between the Dane salts and imines or thioimidates gave 40-60% (.beta.-carbonylvinylamino)-2-azetidinones. E.g., reaction of EtO2CCH:CMeNHCH2CO2- K+ with a methoxyphenyldihydroisoquinoline (Et3N, -25.degree.) gave 80% I, the structure of which was detd. by x-ray crystallog. anal. Mild acid hydrolysis of the vinylamino side chains followed by acylation gave the title compds. Isotope-labeled .beta.-lactams and intermediates for some .beta.-lactam antibiotics were prepd. by this method.
IT **54679-27-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(condensation reaction of, with Dane salt in .alpha.-amido-.beta.-lactam prepn., stereospecific)
RN 54679-27-5 CAPLUS
CN Pyrimidine, 1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-1,4,5,6-tetrahydro-2-(methylthio)- (9CI) (CA INDEX NAME)



L11 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:140071 CAPLUS
DN 82:140071
TI Synthesis of exocyclic thioanalogs of azacepham
AU Bose, Ajay K.; Kapur, J. C.; Manhas, M. S.
CS Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, USA
SO Synthesis (1974), (12), 891-4
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
AB Azacephams I (R = CO2Et, COCH2Ph, phthalimidoacetyl; R1 = SMe, SCH2Ph; R2 = OPh, phthalimidoacetyl, OCH2Ph, OMe, N3) were prepd. by treating tetrahydropyrimidines II (R = H, R1 = SMe, SCH2Ph) with the acyl chloride and treating II (R = CO2Et, COCH2Ph, phthalimidoacetyl; R1 = SMe, SCH2Ph) with R2CH2COCl. I (R = COCH2OPh, R1 = SMe, R2 = OPh) was obtained in 1 step from II (R = H, R1 = SMe) and PhOCH2COCl. Redn. of I (R = phthalimidoacetyl, R1 = SMe, R2 = N3) and acylation gave I (R = phthalimidoacetyl, R1 = SMe, R2 = NHCOCH2OPh). Oxidn. of I (R = COCH2Ph, R1 = SMe, R2 = OPh) yielded I (R = COCH2Ph, R1 = OH, R2 = OPh).
IT **54679-26-4P 54679-27-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with substituted acetyl chlorides)
RN 54679-26-4 CAPLUS
CN Pyrimidine, 1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-1,4,5,6-tetrahydro-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 54679-27-5 CAPLUS
CN Pyrimidine, 1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-1,4,5,6-tetrahydro-2-(methylthio)- (9CI) (CA INDEX NAME)



L11 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1974:132361 CAPLUS
DN 80:132361
TI Polyfluoroheterocyclic compounds. XXIII. Monoenes and dienes derived by the fluorination of hexafluorobenzene and of perfluoro and chlorofluoro heteroaromatic compounds. Mechanism for fluorination by cobalt fluorides
AU Chambers, Richard D.; Clark, David T.; Holmes, Thomas F.; Musgrave, W. Kenneth R.; Ritchie, Ian
CS Chem. Dep., Univ. Durham, Durham, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1974), (1), 114-25
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
AB C6F6 with CoF3 and CaF2 gave perfluoro-1,4-cyclohexadiene and -cyclohexene. Similarly chlorofluoropyridines gave perhalodi- and -tetrahydropyridines and small amts. of acylic azaalkenes. Tetrafluoropyrazine gave 5,6-dihydrohexafluoropyrazine. Calcns. of charge and spin ds. on the atoms in the ring at various stages in the fluorination were made and a mechanism involving, at each stage, the quenching of the first formed radical cation by F- and then by F was suggested. The formation of perfluoro-1,1'-bi-1,3-diazacyclohex-2-enyl from tetrafluoropyrimidine supported the mechanism.
IT **52126-62-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 52126-62-2 CAPLUS
CN 1,1'(4H,4'H)-Bipyrimidine, 2,2',4,4,4',4',5,5,5',5',6,6,6',6'-tetradecafluoro-5,5',6,6'-tetrahydro- (9CI) (CA INDEX NAME)



same as #23

L11 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1973:97631 CAPLUS
DN 78:97631
TI Thiazole derivatives
IN Tchelitcheff, Serge
PA Societe des Usines Chimiques Rhone-Poulenc
SO Fr. Demande, 9 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2128071	A5	19721020	FR 1971-7287	19710303
	FR 2128071	B1	19740802		
PRAI	FR 1971-7287		19710303		

AB Imidazolinylthiazoles (I, R = Me, Et, Hexyl, PhCH2, 2-pyridylmethyl) were prepd. from 2-bromo-5-nitrothiazole and 2-alkylthio-2-imidazolines. Antibiotic activity data were given for I.
IT **40689-09-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 40689-09-6 CAPLUS
CN Pyrimidine, 1,4,5,6-tetrahydro-2-(methylthio)-1-(5-nitro-2-thiazolyl)-(9CI) (CA INDEX NAME)



L11 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1971:22905 CAPLUS
DN 74:22905
TI Antiinflammatory alkylthioimidazolines, tetrahydropyrimidines, and tetrahydrodiazepines
IN Eberle, Marcel K.
PA Sandoz Inc.
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3536714	A	19701027	US 1967-679635	19671101
PRAI US 1967-679635		19671101		

AB The title compds., I, useful as antiinflammatory agents were prepd. by acylation of the appropriate amine. I prepd. were (R and X given): Ph, CH2CH2; o-BrC6H4, CH2CH2; 3-pyridyl, CH2CH2; 4-pyridyl, CH2CH2; 2-(p-chlorobenzoyl)phenyl, CH2CH2; 2-pyridyl, 104.degree.; pyridyl (CH2)3.
IT **30156-32-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 30156-32-2 CAPLUS
CN Pyrimidine, 1,4,5,6-tetrahydro-2-(methylthio)-1-nicotinoyl- (8CI) (CA INDEX NAME)





```
=> d his

     (FILE 'HOME' ENTERED AT 08:27:19 ON 15 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 08:27:25 ON 15 DEC 2003
L1             SCREEN 1839
L2             SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L3             STRUCTURE UPLOADED
L4             QUE L3 AND L1 NOT L2
L5             SCREEN 1839
L6             SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L7             STRUCTURE UPLOADED
L8             QUE L7 AND L5 NOT L6
L9           1 S L8 SSS SAM
L10         71 S L8 SSS FUL

     FILE 'CAPLUS' ENTERED AT 08:29:53 ON 15 DEC 2003
L11        34 S L10

     FILE 'CAOLD' ENTERED AT 08:30:43 ON 15 DEC 2003

=> s l10
L12         1 L10

=> d l12 bib,hitstr
```

L12 ANSWER 1 OF 1 CAOLD COPYRIGHT 2003 ACS on STN
AN CA57:16568b CAOLD
TI xanthene and thiaxanthene cyclic amidines
AU Faust, John A.; Sahyun, M.
DT Patent
TI xanthene and thiaxanthene cyclic amidines
AU Sahyun, Melville
DT Patent

PATENT NO.	KIND	DATE
US 3042674		1962

IT **98470-57-6**
RN 98470-57-6 CAOLD
CN Pyrimidine, 1,4,5,6-tetrahydro-1-(thioxanthen-9-ylmethyl)-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

Same as #34.

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               3.02     307.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00     -22.13

STN INTERNATIONAL LOGOFF AT 08:31:07 ON 15 DEC 2003
```